Integrated Ventures Inc (INTV): IMO one of the most explosive bitcoin tr...

IMO one of the most explosive bitcoin trades

EliSmith · 2025-03-07T21:42:52.7300000Z

IMO one of the most explosive bitcoin trades will be MSTU when MSTR takes off.

Play Episode

5min

Proactive - Interviews for investors

Zero Candida begins trading on OTCQB, advances AI-driven women’s health solutions

Zero Candida Co-Founder and CEO Eli Ben-Haroosh joined Steve Darling from Proactive to announce that the company’s common shares are now trading on the OTCQB Venture Market under the ticker "ZCTFF", alongside its existing listings on the TSX Venture Exchange and Frankfurt Stock Exchange. Ben-Haroosh emphasized that this milestone expands Zero Candida’s market presence, enhances strategic partnerships, and broadens the company’s investor base to support its AI-driven medical technology innovations. Zero Candida is pioneering a novel, non-drug treatment for Vulvo-Vaginal Candidiasis (VVC)—a condition affecting approximately 75% of women globally, with rising resistance to conventional antifungal treatments. The company is developing a tampon-like medical device that utilizes artificial intelligence and therapeutic blue light at a precise wavelength and intensity to eradicate Candida fungus. Early proof-of-concept (POC) studies have demonstrated an impressive 99.999% success rate in treating infections. With drug-resistant cases of recurrent VVC on the rise, Zero Candida’s innovative approach offers a groundbreaking alternative to existing treatments. Zero Candida has completed its preclinical trials with what Haroosh said was “100% safety,” and is preparing for clinical trials by the end of 2025, with market entry targeted after 2026 following FDA approval. #proactiveinvestors #zerocandida #tsxv #zct #WomensHealth #CandidaTreatment #MedicalDevice #Telemedicine #AIinHealthcare #NonDrugTherapy #OTCQB #HealthcareInnovation #FungalInfection

Proactive - Interviews for investors

Arizona Gold & Silver: 8 for 8 success at Philadelphia Project

Arizona Gold & Silver Inc. CEO Mike Stark takes Proactive's Stephen Gunnion through the latest drilling results at the Philadelphia Project in Arizona. Stark highlighted that the company has achieved an 8 for 8 success rate in its infill drilling program, demonstrating strong mineralization both along strike and down dip. Discussing the Rising Fawn target, he noted the consistency of grades between 1.0 to 1.5 grams per tonne, with a 50-meter-wide vein extending beyond 200 meters in depth. This consistency supports the company’s goal of developing a bulk-tonnage, low-grade, heap-leachable resource. Additionally, Stark mentioned that hole 136 could be one of the most promising yet, with visual indicators suggesting high-grade mineralization. He also confirmed that holes 137, 138, and 139 have been completed, with assay results expected soon. Looking ahead, the company remains focused on further drilling and analyzing upcoming assay results, which could influence the next phase of exploration. Stark also noted a strengthened treasury following recent warrant and option exercises, ensuring continued progress at the Philadelphia Project. Stay tuned for more updates on Arizona Gold & Silver’s drilling developments. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for future insights. #GoldExploration #MiningStocks #ArizonaGold #SilverMining #DrillingResults #Investing #PreciousMetals #StockMarket #GoldInvesting #PhiladelphiaProject

Proactive - Interviews for investors

Greatland Gold reveals strong inaugural resources estimate for Telfer gold and copper mine

Greatland Gold PLC (AIM:GGP, OTC:GRLGF) CEO Shaun Day talked with Proactive about the company’s latest mineral resource update and its upcoming dual listing on the ASX. The update confirms 10.2 million ounces of gold and 387,000 tonnes of copper, significantly expanding the company's resource base. Day highlighted that more than 55% of these resources fall under the measured and indicated category, allowing for future conversion to reserves. The company has also added 3.2 million ounces of gold and 117,000 tonnes of copper at the Telfer mine, strengthening its position in the market. "The size of the prize here in terms of life extension is really significant," he stated. The CEO also discussed Greatland Gold’s upcoming ASX listing, set for June 2025, which will broaden investor access and enhance market visibility. "We believe this cross-listing will unlock new demand from Australian investors and provide indexation benefits while maintaining our London listing," Day explained. Additionally, the company is ramping up exploration with six drill rigs in operation, aiming to further extend Telfer’s mine life and identify new mineralisation zones. Upcoming milestones include the March quarterly results in April and a reserve update later in the year. Stay tuned for more updates from Proactive. If you found this video helpful, give it a like, subscribe to our channel, and turn on notifications for the latest insights. #GreatlandGold #GoldMining #MiningStocks #ASXListing #GoldInvesting #TelferMine #CopperMining #MiningNews #ResourceUpdate #GoldStocks

Proactive - Interviews for investors

Protalix BioTherapeutics pipeline eyes gout treatment as financial strength fuels future growth

Protalix BioTherapeutics Chairman Dr Eliot Forster joined Steve Darling from Proactive to discuss the company’s innovative approach to drug manufacturing, which leverages plant cells instead of traditional mammalian cells. This unique method enhances purity, sustainability, and reproducibility, setting Protalix apart in the biotech industry. Forster highlighted the company's commercial success, noting that Protalix has two marketed products through partnerships with Pfizer and Chiesi. He emphasized the company’s strong financial position, having repaid all outstanding debt and operating without warrants, reinforcing its ability to drive long-term growth. A key focus of the discussion was PRX-115, Protalix’s experimental treatment for severe gout. In 2024, the company completed a first-in-human study with promising results. A Phase 2 trial is scheduled for 2025, and Forster expressed optimism about its potential to address a significant unmet medical need. Beyond PRX-115, Forster detailed the company’s strong financial performance in 2024, describing it as a breakthrough year fueled by increased revenue from its three business streams. Looking ahead, Protalix is actively advancing treatments for rare diseases, including renal conditions, as it continues to expand its innovative pipeline. #proactiveinvestors #protalixbiotherapeutics #nyseamerican #plx #Biotech #DrugDevelopment #GoutTreatment #Pharmaceuticals #EliotForster #PRX115 #HealthcareInnovation #ProactiveInvestors

Followers	10
Posts	1798
Boards Moderated	0
Alias Born	08/26/2019

Volume:	2,610
Day Range:	0.2329 - 0.2329
Bid:	0.2329
Ask:	0.291
Last Trade Time:	12:01:40 PM EDT
Total Trades:	8

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

INTV Detailed Quote

Recent INTV News

More INTV News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent INTV News

Go Ad-Free